Skip to main content

Clinical Trial Results


Dr. Andrew Bellinger, Dr. Sek Kathiresan and Dr. C. Michael Gibson Discuss: Safety and Pharmacodynamic Effects of VERVE-101, an Investigational DNA Base Editing Medicine Designed to Durably Inactivate the PCSK9 Gene and Lower LDL Cholesterol – Interim Results of the Phase 1b heart-1 Trial

Disclosures: TBD